Assessing key model parameters for economic evaluation of pandemic influenza interventions: the data source matters. Naiyana Praditsitthikorn,a,b Surachai Kotirum,a Adun Mohara,a Kuntika Dumrongprat,a Roman Perez Velasco,c Yot Teerawattananona aHealth Intervention and Technology Assessment P

Health technology assessments as a mechanism for increased value for money: recommendations to the Global Fund. Yot Teerawattananon1*, Kate McQueston2, Amanda Glassman2, Jomkwan Yothasamut1,2 and Chaw Yin Myint1,2 Abstract The Global Fund is experiencing increased pressure to optimize resul

Advanced health biotechnologies in Thailand: redefining policy directions. Román Pérez Velasco1*, Usa Chaikledkaew2,3, Chaw Yin Myint2 , Roongnapa Khampang2 , Sripen Tantivess2 and Yot Teerawattananon2* Abstract Background: Thailand faces a significant burden in terms of treating and managi

Universal coverage of renal dialysis in Thailand: promise, progress, and prospects. Sripen Tantivess, senior researcher 1, Pitsaphun Werayingyong, researcher 1, Piyatida Chuengsaman, nephrologist 2, Yot Teerawattananon, programme leader 1 1.Health Intervention and Technology Assessment Program

Involvement of consumers in health technology assessment activities by INAHTA agencies. David Haileya1, Sophie Werköa2, Rugayah Bakria3, Alun Camerona4, Britta Göhlena5, Susan Mylesa6, Jasmine Pwua7 and Jomkwan Yothasamuta8 For the INAHTA Working Group on Impact of HTA a1 University of Wollong

This issue of the HITAP Newsletter offers articles and stories of priority setting in the context of real world examples and practices that relate to the development of a benefits package for UHC. We hope to bring our readers towards a closer understanding of the means with which we can achieve equi

Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter? Thavorncharoensap M1, Teerawattananon Y, Natanant S, Kulpeng W, Yothasamut J, Werayingyong P 1Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Thailand ; Heal

Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. Waranya Rattanavipapong1, Tanunya Koopitakkajorn1, Naiyana Praditsitthikorn1,2,*, Surakameth Mahasirimongkol3 andYot Teerawattananon1 Summary Purpose There is strong evidence o

Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: Protection at what price in the Thai context? Wantanee Kulpenga, b, , , , Pattara Leelahavaronga, , Waranya Rattanavipaponga, , Vorasith Sornsrivichaib, , Henry C. Baggettc, , Aronrag Meeyaia, d, , , Warunee Punpaniche, ,

A cost–utility analysis of alternative drug regimens for newly diagnosed severe lupus nephritis patients in Thailand. Adun Mohara1, Román Pérez Velasco1, Naiyana Praditsitthikorn1,2, Yingyos Avihingsanon3 and Yot Teerawattananon1 1Health Intervention and Technology Assessment Program (HITAP),